版本:
中国

BRIEF-Atara Bio granted access to priority medicines

Oct 18 Atara Biotherapeutics Inc :

* Atara bio granted access to priority medicines (prime) regulatory support for allogeneic epstein-barr virus (ebv)-specific cytotoxic T lymphocytes (ctl) for treatment of ebv-associated post transplant lymphoproliferative disorder (ebv-ptld)

* Atara biotherapeutics - anticipates initiation of 2 phase 3 trials in RituxiMab refractory EBV-PTLD after HCT or solid organ transplantlater this year Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐